Luoxin Pharmaceutical (shanghai) Co., Ltd.

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Medshine Discovery Inc.

F. Hoffmann-la Roche Ag

Luoxin Pharmaceutical Co., Ltd.

Jiaqiang Dong

Shuhui Chen

Jian Li

Henner Knust

Bernd Buettelmann

Charles Z Ding

Jianyu Lu

Guoping Hu

Bo Han

Lihong Hu

Tie-Lin Wang

Huijun He

Shenyi Shi

Kevin X Chen

Weidong Li

Xu Zeng

Bin Shi

Xiaobing Yan

Zhijuan Chen

Yuekun Nie

Jianglei Huang

Wenqian Yang

Provided are a salt form of an estrogen receptor down-regulator, a crystalline form thereof, and a preparation method therefor

Salt form of estrogen receptor downregulator, crystalline form thereof, and preparation method therefor

Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof. 

Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

Disclosed are a crystal form of an estrogen receptor inhibitor and a preparation method therefor, in particular disclosed are a crystal form A of a compound of formula (I) and a preparation method therefor, and the use of the crystal form in the preparation of a drug for treating breast cancer. 

Crystal form of estrogen receptor inhibitor and preparation method therefor

Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers. 

Indolo substituted piperidine compound as estrogen receptor down-regulator

Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer. 

Substituted-indole-compounds as estrogen receptor down-regulators

Growing community of inventors

Shanghai, China

Jiaqiang Dong